NASDAQ
31.23USD
-2.57 (-7.60%)
We have scored 23 news catalysts on Kodiak Sciences Inc. (KOD) over the past 12 months. The biggest single-day move next to one of them came Mar 27, 2026, when KOD closed −6.9%: “Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?”. Coverage across the window leans positive (average ticker sentiment +0.44). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
2.18
52W range
10.94-47.84
Day range
30.80–34.48
Open
34.10
Prev close
33.80
Volume
572.2K
Avg volume
699.7K
Dividend
0.00
IPO
2018-10-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kodiak Sciences Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KOD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
